2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1814

Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients
Abstract Number: 2962

Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
Abstract Number: 343

Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
Abstract Number: 2770

Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study
Abstract Number: 499

Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Abstract Number: 451

Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman
Abstract Number: 602

Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study
Abstract Number: 1485

Efficacy of Yttrium-90 Radiosynovectomy in Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome
Abstract Number: 279

Ehlers-Danlos Syndrome Hypermobility Type (Type III) Is Associated with Rheumatological Conditions
Abstract Number: 856

Elderly Versus Younger Patients with ANCA-Associated Vasculitis
Abstract Number: 784

Electronic Health Record (EHR) As a Powerful Tool to Establish Clinical Research Lupus Cohorts
Abstract Number: 1994

Electronic Patient Reported Outcome Measures in Systemic Lupus Erythematosus : A Potential Disease Modifying Impact on the Management of Disease Activity Flares and Damage Accrual
Abstract Number: 2660

Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Abstract Number: 523

Elevated Antibody Response to Porphyromonas Gingivalis Detected in Sera Years before the Clinical Onset of Rheumatoid Arthritis
Abstract Number: 2020

Elevated BMI and ACPA Together Increase RA Risk and Independently Accelerate Time to RA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].